ABVC BioPharma, Inc. ( (ABVC) ) has released a notification of late filing.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
ABVC BioPharma, Inc. has announced a delay in filing its Annual Report on Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the company experiencing challenges in completing its financial statements and other necessary disclosures, which has impacted the completion of its audit. The company expects to file the report within fifteen calendar days following the original deadline. There are no anticipated significant changes in the financial results compared to the previous year. ABVC BioPharma is committed to maintaining compliance and has ensured all other required reports have been filed. The notification was signed by Uttam Patil, the company’s Chief Executive Officer.
More about ABVC BioPharma, Inc.
YTD Price Performance: 34.17%
Average Trading Volume: 521,772
Technical Sentiment Signal: Buy
Current Market Cap: $11.16M
For detailed information about ABVC stock, go to TipRanks’ Stock Analysis page.